Will Amgen downsize the BHBU District Sales Managers

Quote

Anonymous

Guest
How much longer can Amgen maintain all of the BHBU District Sales Managers? If you look at the Q1 final VP report, there are a lot of reps not making the numbers. Why do we need all these District Managers? What is the benefit of keeping them all?
 






The answer is no they don't need them , it was set up for a 700 plus rep unit and only has around 450 ish daily for all the people flocking out of here and will continue to do so.. My guess is that when one mgr. leaves they won't hire another and if they do, later on this year we may combine units with IBU or just restructure in Amgen form!!
 






Have news for you people, no job is safe here. Whether pharma or biotech (no difference BTW) this industry is a sitting duck. See the writing on the wall.

"Pfizer Inc. and rival U.S. drugmakers are poised to report the industry’s biggest drop in quarterly profit in more than four years as the companies cope with record patent losses in 2011.

Earnings at the 11 drugmakers listed in the Standard & Poor’s 500 Index probably fell 1.4 percent in the first quarter, even as overall profits for companies in the index may have gained 12 percent, according to analyst estimates compiled by Bloomberg. Pharmaceutical profits last fell in 2009’s first quarter, and the current drop is the biggest since a 3.5 percent slip in the final quarter of 2006.

Pfizer, Merck & Co. and Bristol Myers Squibb Co. are eliminating jobs, cutting costs and shedding business units to prepare for patent expirations. In 2011, drugmakers face generic rivals to products with $34 billion in yearly sales, a figure 34 percent higher than last year. Sales at risk from patent losses will swell to $147 billion by 2015.

“A brand can lose 40 percent of sales and 50 percent of volume globally in the first two years after generic entry,” said Chris Bowe, a New York-based analyst for Informa Plc, a London industry research firm, “It’s now not uncommon to see a brand lose 50 percent of U.S. sales in two quarters.”

Four U.S. drugmakers report earnings next week. Eli Lilly & Co., based in Indianapolis, will report on April 18, followed by New Brunswick, N.J.-based Johnson & Johnson and New York-based Forest Laboratories Inc. on April 19 and Abbott Laboratories, of Abbott Park, Ill., on April 20. The average quarterly earnings growth for drugmakers was 10 percent since the first quarter of 2007.

Drug profits last quarter were also hampered by the U.S. health-care overhaul, which mandates product discounts for older Americans, as well as price cuts from European drugmakers.

To make up for lost sales, Chief Executive Ian Read at New York-based Pfizer said last quarter he was reviewing possible divestiture of each company division — baby formula, animal health, consumer and established products — to concentrate on drug development. On April 4, Pfizer agreed to sell Capsugel, its smallest unit, which manufactures pill casings, to KKR & Co. for $2.38 billion.

“Everybody knows it’s coming, everyone’s placed their bets,” said Les Funtleyder, a New York-based fund manager at Miller Tabak & Co. “What pharma investors are interested in is pipelines and corporate transactions — either acquisitions or divestitures. That’s going to dominate the discussions.”
 


















strong probability that BHBU will merge with other BU/s.

Consolidation of BHBU RD's DM's and REPs will take place.

More insight will be made public after this week's quarterly results announcement. The Prolia sales results don't lie. Listen to the conf call with Wall Street Analyst and you will see the true state of the Prolia launch to date (terrible) This is not a blockbuster, or even close for osteo market. SG&A for BHBU sales force is not covered by the amount of revenue from Prolia sales to date, and don't even think about profitability.

Ask yourself why the bonus incentive program keeps changing quarter to quarter. hmmm... sinking ship.
 












Anonymous said:
I know for a fact that they are not downsizing and that they will merge the merger and acquisition departments into one.
Click to expand...



Posters 5 and 7, please wake up from your haze. It is GAME OVER!! Every company in this industry will feel it. We are no exception. Also the Easter Bunny is NOT coming this year.
 












Anonymous said:
Posters 5 and 7, please wake up from your haze. It is GAME OVER!! Every company in this industry will feel it. We are no exception. Also the Easter Bunny is NOT coming this year.
Click to expand...

Again, there are no downsizing or merger talks for ANY BU. I know there is a great deal of hostility toward the BHBU, and I am not here to defend them; however facts are facts and you cannot get on this site and scare people by conveying inaccurate information.

Go sell and leave the strategy to those who get paid to develop it. You do your job, they will do the job they are paid to do.
 






Thank you.... well put




Anonymous said:
Again, there are no downsizing or merger talks for ANY BU. I know there is a great deal of hostility toward the BHBU, and I am not here to defend them; however facts are facts and you cannot get on this site and scare people by conveying inaccurate information.

Go sell and leave the strategy to those who get paid to develop it. You do your job, they will do the job they are paid to do.
Click to expand...
 






Anonymous said:
Again, there are no downsizing or merger talks for ANY BU. I know there is a great deal of hostility toward the BHBU, and I am not here to defend them; however facts are facts and you cannot get on this site and scare people by conveying inaccurate information.

Go sell and leave the strategy to those who get paid to develop it. You do your job, they will do the job they are paid to do.
Click to expand...

Anybody ever say your a doochebag. If not then I'm saying it!
 






Top Bottom
Back
Quote